Atherosclerosis is a major risk factor for erectile dysfunction, and loss of endothelium-dependent vasodilation appears early in the development of this disorder. Nitric oxide (NO) appears to be the principle mediator of erectile function and is generated in part by the sinusoidal endothelium. Vascular endothelial growth factor (VEGF) is an angiogenic growth factor and an endothelial cellspeci®c mitogen and the actions of VEGF are coupled to NO. In this preliminary study, we investigated whether VEGF could be used to protect endothelial dependent cavernosal relaxation from the atherosclerotic injury induced by a hypercholesterolemic diet.
Introduction
Estimates of the number of men in the US who suffer from erectile dysfunction conservatively approach 10 million. Demographic trends in the US will lead to a signi®cant increase in the prevalence of this condition. The last decade has seen enormous growth in our knowledge and understanding of erectile function and dysfunction, leading to new approaches and directions in therapy. Nitric oxide (NO) has been identi®ed as the principle mediator of penile cavernosal trabecular smooth muscle relaxation, the central event of erection. The nerves and endothelium of the penis release NO, leading to the generation of cyclic GMP, the secondary messenger of cavernosal smooth muscle relaxation. 11 Recognition and understanding of the critical nature of this pathway has led to the introduction of the ®rst effective oral therapy for erectile dysfunction, sildena®l citrate. However, to date, all available therapies for erectile dysfunction, including sildena®l citrate, have been compensatory; none of these treatments protect against or reverse underlying pathophysiological events.
The vascular endothelium plays an essential role in regulating cavernosal smooth muscle tone. Many endothelial factors have a role in erection, among them endothelium derived relation factor-NO (EDRF-NO), the vasodilator prostacyclin, the vasoconstrictors thromboxane A2 and endothelin. All work together to regulate vasomotion and to preserve a smooth, nonthrombotic luminal surface. EDRF-NO is produced at a basal rate by the nerves and endothelial cells, and is stimulated in response to NANC neural impulses, resulting in erection. In atheroslerosis, the response of the vascular endothelium to vasodilatory stimuli may be compromised even before the appearance of atherosclerotic lesions. Defects in endothelial function may be the ®rst sign of atherosclerosis. In a study of cardiovascular disease, patients with hyperlipidemia but without atherosclerotic lesions showed decreased sensitivity to endothelium dependent vascular relaxation induced by acetylcholine. 2 Similarly, hypercholesterolemia impairs corporal smooth muscle relaxation, hence vasodilation in the penis.
Vascular endothelial growth factor (VEGF) stimulates endothelial cell growth and has been shown to modulate angiogenesis. NO lies`downstream' on the angiogenic pathway of VEGF, and VEGF modulates microvascular permeability via a signaling cascade that involves NO. VEGF treatment has resulted in both an acute (1 h) and chronic ( b 24 h) stimulation of NO production in human endothelial cells. 3 Moreover, VEGF has been shown to signi®cantly improve blood¯ood in chronic ischemia in other organs. 3 ± 5 VEGF has been shown to improve myocardial blood¯ow in the ischemic porcine heart and the ischemic rabbit hind limb with a single intra-arterial bolus. 4, 5 Preliminary data from multicenter clinical trials using VEGF therapeutically in patients with severe ischemic end-stage heart disease appear promising.
Previous studies by Azadzoi and de Tejada, and in our laboratory have demonstrated that hypercholesterolemia in the New Zealand white rabbit model reduced both endothelium dependent and endothelium independent relaxation of the corpus cavernosum. 6, 7 Hypercholesterolemic injury also induces morphological changes in the corporal smooth muscle. 9 Another study using the same model showed that there is a close relationship between prolonged atherosclerotic occlusion of major penile arteries and the development of corpora cavernosal veno-occlusive dysfunction. 8, 9 VEGF has been previously shown to stimulate production of NO from rabbit and human endothelial cells. 10 In this preliminary study, we investigated whether VEGF could be used to protect endothelial dependent corporal smooth muscle relaxation from hypercholesterolemia induced injury in New Zealand white rabbits.
Materials and methods
Twenty-eight male New Zealand white rabbits weighing 2 ± 2.5 kg were used in a two arm study. There were four groups: (1) eight rabbits were fed a 1% cholesterol diet (Harland Teklab, Wisconsin) for 4 weeks and received three (weekly) intracavernosal injections of saline; (2) eight rabbits were fed a 1% cholesterol diet for 4 weeks and received three (weekly) intracavernosal injections of 0.3 mg VEGF; (3) six rabbits were given an intracavernosal injection of normal saline and fed standard rabbit chow (Purina Mills, Inc., St. Louis, Missouri) for 4 weeks; (4) six rabbits were given an intracavernosal injection of 1 mg of VEGF and fed standard rabbit chow for 4 weeks. Random serum total cholesterol levels were measured at the beginning of the study and after 4 weeks of the 1% cholesterol diet, no other biochemical levels were evaluated. At the end of 4 weeks, each rabbit underwent total penectomy and was then killed (see later). No other organ systems were evaluated. Strips of corpora cavernosa were suspended in tissue baths (two per rabbit), and isometric tension studies were performed. Dose ± response curves for norepinephrine were generated ®rst in each strip to assess adrenergic-mediated cavernosal smooth muscle contraction. Dose ± response curves for histamine were generated to assess histamine receptor mediated contraction of cavernosal smooth muscle. Submaximal contraction was then produced with 10 À5 concentration of norepinephrine and dose ± response curves were then generated to evaluate endothelial-dependent (acetylcholine (ACH)) smooth muscle relaxation. A submaximal contraction was produced using 10 À5 concentration of norepinephrine and dose ± response curves were then generated to evaluate endothelial-independent (sodium nitroprusside (SNP)) smooth muscle relaxation.
Rabbit chowafeeding protocol
The custom 1% cholesterol diet consisted of 24,750 g of standard rabbit chow, 250 g cholesterol, and 50 g calcium propionate per 25 kg barrel. Standard rabbit chow contained b 2% fat, b 14% protein,`20% ®ber and`11% ash. Each rabbit was fed and consumed 120 g of rabbit chow per day, in accordance with the Duke University Medical Injected VEGF protects endothelial dependent corpora cavernosal muscle relaxation GD Henry et al Center Vivarium (Department of Laboratory Animal Resources) feeding policy.
Tissue
Cavernosal tissue was obtained under general anesthesia induced with Ketamine 50 mgakg SC (Ketaset, Bristol Laboratories, Syracuse, New York) and Xylazine 30 mgakg SC (Rompun, Mobay Corp., Shawnee, Kansas). The penis was excised en bloc and placed in warm Krebs solution, where the corpora cavernosa were sharply dissected from the tunica albuginea producing a strip (approximately 0.3 6 0.3 6 0.7 cm) from each corpus. The strips were then mounted in the oxygen tissue baths. After tissue collection, the rabbits were euthanized by overdose of intravenous sodium pentobarbitol (100 mgakg to effect). Care was taken throughout the procedure to minimize tissue manipulation.
Animal care complied with the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health (US Department of Health and Human Services) and the Principles of Laboratory Animal Care as formulated by the National Society for Medical Research. The Institutional Animal Care and Use Committee approved the experimental protocol.
Tissue chambers
Each cavernosal strip was suspended from two hooks and placed in a 5 ml tissue bath (Kent Scienti®c Corp., Litch®eld, Connecticut). One end was attached to the bottom of the bath and the other end was attached to a force transducer (FTO3, Grass Instruments, Quincy, MA) for determination of isometric tension. The bath was ®lled with a modi®ed Kreb's physiological salt solution with the following millimolar composition: NaCl 122, KCI 4.7, MgCl 2 1.2, CaCI 2 2.5, NaHCO 3 15.4, KH 2 PO 4 1.2, and glucose 5.5. A circulating water bath kept tissue chamber temperatures at 37 C. Continuous aeration with 95% oxygen and 5% carbon dioxide maintained a pH of 7.4.
Optimal isometric tension determination
Each of the force transducers was connected to a transducer positioner enabling preload tension adjustment. Following suspension in the tissue chambers, the tension was periodically adjusted (at least every 15 min) until the strip equilibrated at 0.5 g (usually 2 h). The optimal preload tension was then determined by contracting the tissue with 60 mM KCI Krebs solution (KCI 60 mmolal, NaCl 667 mmolal, MgCI 2 1.2 mmolal, CaCI 2 2.5 mmolal, NaHCO 3 15.4 mmolal, KH 2 PO 4 1.2 mmolal and glucose 5.5 mmolal) at increasing levels of preload (0.5 g increments). Optimal preload tension was de®ned as that level of preload at which a further increase in tension failed to generate an increase of at least 10% in active tension: total tension minus resting tension. All subsequent testing was then performed at the determined optimal resting tension for each strip. Tension was monitored by fourchannel polygraph (Grass 7D, Grass Instruments).
Isometric tension studies
The tissue was washed with Kreb's solution every 15 min after each study until return to baseline (at least 1 h). Dose ± response curves for norepinephrine were obtained by cumulative addition of norepinephrine (10 À9 ± 10 À4 M) in logarithmic increments. Next, dose ± response curves for histamine were obtained by cumulative addition of histamine (10 À8 ± 10 À4 M) in logarithmic increments.
Norepinephrine and histamine contractions at each dose are expressed as a percentage of maximal tension generated of each drug respectively. Each strip was then precontracted with 10 À5 M of norepinephrine for assessment of relaxation by ACH. Dose ± response curves were preformed by cumulative addition of ACH (10 À8 ± 10 À3 M) in logarithmic increments after steady-state contraction was attained. Lastly, 10 À5 M of norepinephrine was used to precontract each strip for assessment of relaxation by SNP. Dose ± response curves were preformed by cumulative addition of SNP (10 À8 ± 10 À4 M) in logarithmic increments after steady-state contraction was attained. Relaxation in response to ACH and SNP is expressed as a percentage of the active tension generated by the 10 À5 of norepinephrine.
Statistical analysis
Data are expressed as means AE the standard error of the mean with n representing the number of cavernosal strips that were obtained. Dose ± response curves were compared by Student's t-test. Statistical signi®cance was considered when P`0.05. ED 50 , ED 25 and ED 75 were determined using logistic regression with logit transformation.
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Results

Serum total cholesterol levels
There was a signi®cant elevation in serum total cholesterol levels from a normal diet (38.7 AE 5.53 mgadl) to (727 AE 75.6 mgadl) after 4 weeks of a 1% cholesterol diet with P`0.01. There were no overt toxicity or adverse effects visible after injections of VEGF in our animals.
Isometric tension studies
There were no signi®cant differences between the groups for the level of preload for optimal contraction or in the maximal active tension in response to 60 mM KCI Kreb's solution.
Norepinephrine and histamine
Norepinephrine and histamine produced a doserelated contraction in all four groups. There was a slight increase in sensitivity to norepinephrine for the two cholesterol fed groups vs the two normal diet groups. However, the increase in sensitivity did not reach statistical signi®cance (P b 0. Figure 3 ). There was a signi®cant difference in the relaxation to SNP of the hypercholesterolemic rabbits that received VEGF (À129.4 AE 24) vs NS (115.0 AE 18) with P 0.033.
Comment
Erectile dysfunction was formerly felt to be primarily a psychological disorder and available therapies Injected VEGF protects endothelial dependent corpora cavernosal muscle relaxation GD Henry et al were limited. Recent advances in our understanding of the physiology and disorders of erectile function have led to new approaches and directions in therapy. Vascular endothelial growth factor is an endothelial cell-speci®c mitogen in vitro and an angiogenic growth factor in vivo. 3,4,10,12,13 Persistent vasodilation and increased vascular permeability initially characterize angiogenesis, the process by which new blood vessels are formed from preexisting ones. The action of VEGF is coupled to NO. For example, VEGF appears to modulate microvascular permeability via a signaling cascade that involves NO; in addition, NO mediates the angiogenic activity of VEGF. 12,13 VEGF upregulates endothelial cell NO synthase (ecNOS) enzyme and elicits a biphasic increase in the production of endothelial NO in human endothelial cells. 3, 10 Hood et al go on to state that VEGF might regulate endothelial production of NO. 3 NO has been shown to be a downstream imperative of VEGF; L-NAME (a NO inhibitor) completely blocked angiogenesis induced by VEGF. 12 Within the vascular wall, VEGF can be produced by vascular smooth muscle cells (SMCs) and can thereby modulate endothelial cell (EC) functions via paracrine pathway. Moreover, VEGF stimulates production of NO from rabbit and human ECs. The vascular endothelium plays an essential role in regulating cavernosal smooth muscle tone. Many endothelial factors have been shown to have a role in erection including: (1) endothelium derived relation factor-NO; (2) the vasodilator prostacyclin; (3) the vasoconstrictors thromboxane A2; and (4) endothelin. All work together to regulate vasomotion and to preserve a smooth, nonthrombotic luminal surface. EDRF-NO is produced at a basal rate by the nerves and endothelial cells, and is stimulated in response to NANC neural impulses, resulting in erection. Increased total cholesterol and a low level of high-density lipoprotein cholesterol have previously been identi®ed as important predictors of erectile dysfunction. Every mmolal of increase in total cholesterol was associated with 1.32 times the risk of erectile dysfunction. 14 In atheroslerosis, the response of the vascular endothelium to vasodilation stimuli may be compromised even before the appearance of atherosclerotic lesions. Defects in endothelial function may be the ®rst sign of atherosclerosis. In a study of cardiovascular disease, patients with hyperlipidemia but without atherosclerotic lesions showed decreased sensitivity to endothelium dependent vascular relaxation induced by ACH. Similarly, hypercholesterolemia impairs vasodilation in the penis.
Previous studies by Azadzoi and de Tejada, and in our laboratory have demonstrated that hypercholesterolemia in the New Zealand white rabbit model reduced both endothelium dependent and endothelium independent relaxation of the corpus cavernosum. The same investigators showed that Injected VEGF protects endothelial dependent corpora cavernosal muscle relaxation GD Henry et al there is a close relationship between prolonged atherosclerotic occlusion of major penile arteries and the development of corpora cavernosal venoocclusive dysfunction. 9 Hypercholesterolemic injury also induces morphological changes in the corporal smooth muscle. 8 The ability of growth factors to protect the endothelium from hypercholesterolemic injury has been demonstrated previously in the rabbit thoracic aorta. 15 After feeding on a 2% cholesterol diet for 6 weeks 14 New Zealand white rabbits received twiceweekly intravenous boluses of either 2.5 mg basic ®broblast growth factor (bFGF) (hypercholesterolemic bFGF group, n 6) or placebo (hypercholesterolemic control group, n 8) for 3 weeks and were killed for assessment of in vitro vasoreactivity and for histological analysis. Endothelium-dependent responses to ACH were reduced in the hypercholesterolemic control group compared with normal rabbits. Hypercholesterolemic animals treated with bFGF had signi®cantly better endothelium-dependent responses than hypercholesterolemic rabbits not treated with bFGF. Endothelium-independent responses did not differ signi®cantly among the three groups. These results show that, in this model of atherosclerosis, bFGF has a highly bene®cial effect on the functional responses of atherosclerotic vessels and does not have a deleterious effect on the degree of plaque formation. In our study, the VEGF was given weekly for 3 weeks to see if this had a protective effect. Penile tumescence (Figure 1 ) was seen after most injections of VEGF.
In our study there were no signi®cant differences in any of the contraction or relaxation results in the normal diet groups. The cholesterol groups were more sensitive to norepinephrine than the normal diet groups but this trend did not reach statistical signi®cance, and all groups showed dose-related contraction to histamine, which is in accordance with previous studies. No adverse reactions to VEGF were seen in any of the animals.
SNP is a direct NO donor and thereby directly causes smooth muscle relaxation, independent of the endothelium. Intracavernosal injections of SNP have demonstrated penile tumescence in humans. 16 There was a signi®cant difference in the sensitivity to SNP of the hypercholesterolemic rabbits that received VEGF vs NS at all doses. The ability of ACH to produce smooth muscle relaxation is dependent on intact endothelium. The hypercholesterolemic rabbits receiving VEGF had signi®cantly higher relaxation to ACH at all doses compared to the hypercholesterolemic rabbits that received NS. Here VEGF appears to have protected the ability of the endothelium to produce a higher level of relaxation, possibly due to a higher production of NO. As ACH causes endothelial-mediated relaxation of the smooth muscle, the signi®cance of VEGF treatment appears to be an increase in NO production by the endothelium as shown in other studies. 3, 10 This preliminary report demonstrates that VEGF appears to protect endothelial cell dependent smooth muscle function in the corpora cavernosa of hypercholesterolemic rabbits when given at the time of the initial injury. Further study is required to determine whether VEGF administration can reverse endothelial dysfunction once it has been induced by atherosclerosis.
